« Study Finds High-Impact Medical Journals Guilty of Anti-Industry Bias | Main | Europe Undermining Innovation by Cutting Drug Prices »

April 12, 2012

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00e5520572bb8834016303751979970d

Listed below are links to weblogs that reference FDA: Committee Recommends Exploring Anti-NGF Biologics for Chronic Pain Management:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

The nerve grouth factor (NGF), protein discovered by Rita Levi-Montalcini, was found for first time in patients with knee osteoarthritis by us in 1992 (Arthritis and rheumatism 35, 3: 351-355). Since then we have done studies and found that the NGF has a anti-inflammatory activity (Clinical and experimental rheumatology 1997, 15: 433-438)and effect repairer skin ulcers (Lancet 2000, 356:1739-1740). These effects are mediated by lymphocytes Th2 and by mastcells that release cytokines such as IL-4 and IL-10.
The joint destruction and osteonecrosis by tanezumab are due to blockage of anti-inflammacory activities and angiogenesis of the NGF.
The NGF is a potent anti-inflammatory and promotes healing of skin ulcers.

The comments to this entry are closed.

Sponsors

Enter your Email:
Preview | Powered by FeedBlitz

October 2014

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31